As a new mutant strain of coronavirus originating from the South American Amazon rages in Brazil, a preliminary study has found that China’s Keleflor (CoronaVac) vaccine from Kexing Holdings may be “not so effective,” according to a March 8 report in the Wall Street Journal.
The report said researchers from Brazil, the United Kingdom and the United States found that in eight people who received the Chinese Krilaford vaccine five months ago, the plasma in the body “failed to effectively neutralize” the new Amazon strain known as P.1. The study also did not show whether kerafol could prevent humans from contracting the mutated strain, which is one of the main purposes of the vaccination.
Although the study’s sample size was small, the fact that all eight individuals produced the same results is “remarkable,” said De Souza, an author of the study and an academic at the University of São Paulo in Brazil.
So far, China Kexing Holdings Biotechnology Co., which produces the keraflex vaccine, has not responded to the question. The Brazilian government has previously agreed to buy up to 100 million doses of the new crown vaccine developed by China Kexing Holdings in response to the surge in cases.
Recent Comments